QQ客服 官方微博 反馈留言

	Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus
	Cai, Wen; Huang, Jiwei; Yuan, Yichu; Hu, Xiaoyi; Li, Mingyang; Kong, Wen; Zhang, Jin; Guo, Jianming; Chen, Yonghui; Huang, Yiran
刊名	UROLOGIA INTERNATIONALIS
	2018
卷号	101期号:4
关键词	Renal cell carcinoma Tumor thrombus Neoadjuvant therapy Prognosis Sunitinib Sorafenib
ISSN号	0042-1138
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3603141
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Cai, Wen,Huang, Jiwei,Yuan, Yichu,et al. Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus[J]. UROLOGIA INTERNATIONALIS,2018,101(4).
APA	Cai, Wen.,Huang, Jiwei.,Yuan, Yichu.,Hu, Xiaoyi.,Li, Mingyang.,...&Huang, Yiran.(2018).Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus.UROLOGIA INTERNATIONALIS,101(4).
MLA	Cai, Wen,et al."Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus".UROLOGIA INTERNATIONALIS 101.4(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。